General Information of This Drug (ID: DM8D9H5)

Drug Name
Coenzyme Q10   DM8D9H5
Synonyms CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen
Indication
Disease Entry ICD 11 Status REF
Cerebrovascular ischaemia 8B1Z Phase 4 [1]
Pancreatic tumour 2C10 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Squamous cell carcinoma 2B60-2D01 Phase 2 [4]
Epidermolysis bullosa EC3Z Phase 1 [4]
Recurrent glioblastoma 2A00.00 Phase 1 [5]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Coenzyme Q10 + Idarubicin DCM540K Idarubicin Glioblastoma? (Cell Line: T98G) [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01660191) A Study Comparing CoQ10 Levels While Taking 3 Different Statins. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT00604890) Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.